1,012
Participants
Start Date
July 7, 2021
Primary Completion Date
December 14, 2022
Study Completion Date
June 30, 2023
Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Yale New Haven Hospital, New Haven
Collaborators (1)
AstraZeneca
INDUSTRY
Yale University
OTHER